{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:40:31Z","timestamp":1790624431050,"version":"4.1.0"},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The most common non-Hodgkin lymphoma (NHL) subtype is diffuse large B-cell lymphoma (DLBCL). It accounts for roughly 30% of all cases of NHL affecting both nodal and extra nodal sites. There are molecular subtypes of DLBCL, germinal centre subtype (GCB), and activated B-cell (ABC), based on gene expression profiling (GEP), in accumulation to distinct morphological and clinicopathological subtypes. To prognosticate patients, the International Prognostication Index (IPI) and its variants are used. In ABC type DLBCL, limited stage disease is treated with a combination of abbreviated systemic chemotherapy (three cycles) and field radiation therapy. Although advanced stage disease is treated with a full course of chemotherapy as well as novel agents (Bortezomib, Ibrutinib, Lenalidomide). In this review study, we looked at the role of multiple aspects of genetic and microenvironment changes which have effects in DLBCL tumours.<\/jats:p>","DOI":"10.4103\/jfmpc.jfmpc_2432_21","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T06:27:00Z","timestamp":1663050420000},"page":"4151-4158","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment"],"prefix":"10.4103","volume":"11","author":[{"given":"Garima","family":"Mamgain","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Haematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen K.","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Patra","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Naithani","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uttam K.","family":"Nath","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Haematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1200\/JCO.2010.33.3419","article-title":"Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP","volume":"29","author":"Sehn","year":"2011","journal-title":"J Clin Oncol"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"B3-20240828","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1600-0609.2007.00976.x","article-title":"Profiling of diffuse large B-cell lymphoma by immunohistochemistry: Identification of prognostic subgroups","volume":"79","author":"Sj\u00f6","year":"2007","journal-title":"Eur J Haematol"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.leukres.2015.11.001","article-title":"Targeting B-cell non Hodgkin lymphoma: New and old tricks","volume":"42","author":"Solimando","year":"2016","journal-title":"Leuk Res"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/asheducation-2017.1.295","article-title":"Current treatment of double hit and double expressor lymphoma","volume":"2017","author":"Reagan","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B9-20240828","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"12","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"13","author":"Wright","year":"2020","journal-title":"Cancer cell"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nrclinonc.2015.77","article-title":"CtDNA\u2014Identifying cancer before it is clinically detectable","volume":"12","author":"Hutchinson","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/annonc\/mdw029","article-title":"Breakthrough therapies in B-cell non-Hodgkin lymphoma","volume":"27","author":"Cheah","year":"2016","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"B15-20240828","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0752-3","article-title":"Novel and emerging therapies for B cell lymphoma","volume":"12","author":"Ayyappan","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B17-20240828","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"B20-20240828","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci","year":"2018","journal-title":"Blood"},{"key":"B21-20240828","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.immuni.2019.08.006","article-title":"Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma","volume":"51","author":"Meyer","year":"2019","journal-title":"Immunity"},{"key":"B22-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-017-0439-1","article-title":"EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP","volume":"17","author":"Li","year":"2017","journal-title":"Cancer Cell Int"},{"key":"B23-20240828","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrclinonc.2013.110","article-title":"Liquid biopsy: Monitoring cancer-genetics in the blood","volume":"10","author":"Crowley","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"B24-20240828","first-page":"1","article-title":"Liquid biopsy and tumor heterogeneity in metastatic solid tumors: The potentiality of blood samples","volume":"39","author":"Russano","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B25-20240828","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3390\/jcm9030670","article-title":"miR-221-3p regulates VEGFR2 expression in high-risk prostate cancer and represents an escape mechanism from sunitinib in vitro","volume":"9","author":"Krebs","year":"2020","journal-title":"J Clin Med"},{"key":"B26-20240828","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease\u2014latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B27-20240828","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3390\/jcm9020552","article-title":"Bortezomib treatment modulates autophagy in multiple myeloma","volume":"9","author":"Di Lernia","year":"2020","journal-title":"J Clin Med"},{"key":"B28-20240828","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.3390\/jcm8122030","article-title":"Insights into the regulation of tumor angiogenesis by micro-RNAs","volume":"8","author":"Leone","year":"2019","journal-title":"J Clin Med"},{"key":"B29-20240828","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/cancers11020144","article-title":"Systematic review of the potential of MicroRNAs in diffuse large B cell lymphoma","volume":"11","author":"Larrabeiti-Etxebarria","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B30-20240828","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","article-title":"Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin","volume":"164","author":"Snyder","year":"2016","journal-title":"Cell"},{"key":"B31-20240828","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"B32-20240828","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3390\/jcm8070997","article-title":"High-risk multiple myeloma: Integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment","volume":"8","author":"Solimando","year":"2019","journal-title":"J Clin Med"},{"key":"B33-20240828","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/10428190902893835","article-title":"Targeting angiogenesis: A novel, rational therapeutic approach for non-Hodgkin lymphoma","volume":"50","author":"Ruan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"B34-20240828","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/annonc\/mdy450","article-title":"Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue","volume":"29","author":"Ciavarella","year":"2018","journal-title":"Ann Oncol"},{"key":"B35-20240828","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/stem.1556","article-title":"CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment","volume":"32","author":"Kinugasa","year":"2014","journal-title":"Stem Cells"},{"key":"B36-20240828","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/path.5187","article-title":"Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes","volume":"247","author":"Frassanito","year":"2019","journal-title":"J Pathol"},{"key":"B37-20240828","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bbamcr.2015.11.003","article-title":"Tumor microenvironment (TME)-driven immune suppression in B cell malignancy","volume":"1863","author":"Nicholas","year":"2016","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B38-20240828","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2141.2007.06612.x","article-title":"Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma","volume":"138","author":"Hedstr\u00f6m","year":"2007","journal-title":"Br J Haematol"},{"key":"B39-20240828","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1007\/s12032-011-0123-6","article-title":"High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma","volume":"29","author":"Cai","year":"2012","journal-title":"Med Oncol"},{"key":"B40-20240828","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/1-4020-7920-6_9","article-title":"Angiogenesis in leukemia and lymphoma","volume":"121","author":"Kini","year":"2004","journal-title":"Cancer Treat Res"},{"key":"B41-20240828","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1593\/neo.121962","article-title":"The role of angiogenesis in human non-Hodgkin lymphomas","volume":"15","author":"Ribatti","year":"2013","journal-title":"Neoplasia"},{"key":"B42-20240828","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1038\/onc.2014.403","article-title":"The tumor microenvironment shapes hallmarks of mature B-cell malignancies","volume":"34","author":"Shain","year":"2015","journal-title":"Oncogene"},{"key":"B43-20240828","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol"},{"key":"B44-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37273-4","article-title":"Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma","volume":"9","author":"Fornecker","year":"2019","journal-title":"Sci Rep"},{"key":"B45-20240828","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1309\/AJCPJX4BJV9NLQHY","article-title":"The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"135","author":"Meyer","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"B46-20240828","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2012-04-423079","article-title":"A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515","volume":"120","author":"Stopeck","year":"2012","journal-title":"Blood"},{"key":"B47-20240828","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3324\/haematol.2013.100818","article-title":"R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: Final MAIN study outcomes","volume":"99","author":"Seymour","year":"2014","journal-title":"Haematologica"},{"key":"B48-20240828","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol"},{"key":"B49-20240828","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mvr.2008.08.003","article-title":"The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions","volume":"77","author":"Lu","year":"2009","journal-title":"Microvasc Res"},{"key":"B50-20240828","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/leu.2015.302","article-title":"A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma","volume":"30","author":"Suhasini","year":"2016","journal-title":"Leukemia"},{"key":"B51-20240828","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.bjc.6600742","article-title":"Vascular patterns in reactive lymphoid tissue and in non-Hodgkin's lymphoma","volume":"88","author":"Passalidou","year":"2003","journal-title":"Br J Cancer"},{"key":"B52-20240828","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/labinvest.3700697","article-title":"Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy","volume":"88","author":"Gratzinger","year":"2008","journal-title":"Lab Invest"},{"key":"B53-20240828","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.17219\/acem\/61427","article-title":"Angiogenesis in CD5-positive diffuse large B cell lymphoma: A morphometric analysis","volume":"25","author":"Wo\u017anialis","year":"2016","journal-title":"Adv Clin Exp Med"},{"key":"B54-20240828","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm0102-68","article-title":"Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning","volume":"8","author":"Shipp","year":"2002","journal-title":"Nat Med"},{"key":"B55-20240828","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood.V110.11.53.53","article-title":"Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy","volume":"110","author":"Gratzinger","year":"2007","journal-title":"Blood"},{"key":"B56-20240828","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/10428190601083241","article-title":"Angiogenesis in non-Hodgkin's lymphoma: Clinico-pathological correlations and prognostic significance in specific subtypes","volume":"48","author":"J\u00f8rgensen","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"B57-20240828","doi-asserted-by":"crossref","first-page":"605","DOI":"10.4103\/0973-1482.146086","article-title":"Abnormal vascular endothelial growth factor protein expression may be correlated with poor prognosis in diffuse large B-cell lymphoma: A meta-analysis","volume":"12","author":"Jiang","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"B58-20240828","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1080\/10428194.2017.1300893","article-title":"Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma","volume":"58","author":"Yoon","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B59-20240828","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00432-007-0294-x","article-title":"The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: A retrospective study of 97 patients","volume":"134","author":"Ganjoo","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"B60-20240828","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1349-7006.2011.02168.x","article-title":"VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma","volume":"103","author":"Kim","year":"2012","journal-title":"Cancer Sci"},{"key":"B61-20240828","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.18632\/oncotarget.6624","article-title":"Angiomirs expression profiling in diffuse large B-Cell lymphoma","volume":"7","author":"Borges","year":"2016","journal-title":"Oncotarget"},{"key":"B62-20240828","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3960\/jslrt.56.79","article-title":"Treatment of diffuse large B-cell lymphoma","volume":"56","author":"Miyazaki","year":"2016","journal-title":"J Clin Exp Hematop"},{"key":"B63-20240828","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2010-03-276766","article-title":"Immunoblastic morphology but not the immunohistochemical GCB\/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL","volume":"116","author":"Ott","year":"2010","journal-title":"Blood"},{"key":"B64-20240828","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1038\/s41375-019-0478-9","article-title":"Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma","volume":"33","author":"Lupino","year":"2019","journal-title":"Leukemia"},{"key":"B65-20240828","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"B66-20240828","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"2021 Update on diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management","volume":"96","author":"Susanibar-Adaniya","year":"2021","journal-title":"Am J Hematol"},{"key":"B67-20240828","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): A randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"key":"B68-20240828","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","article-title":"R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","volume":"131","author":"Lamy","year":"2018","journal-title":"Blood"},{"key":"B69-20240828","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1200\/JCO.2018.36.15_suppl.7574","article-title":"Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2\u00d72 randomized UNFOLDER trial of the DSHNHL\/GLA","volume":"36","author":"Pfreundschuh","year":"2018","journal-title":"J Clin Oncol"},{"key":"B70-20240828","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d\u2019 Etudes des Lymphomes de l\u2019 Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"B71-20240828","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"key":"B72-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00900-7","article-title":"A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: Final analysis of GOYA","volume":"13","author":"Sehn","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B73-20240828","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1182\/bloodadvances.2020002567","article-title":"A randomized phase 2\/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: The JCOG0601 trial","volume":"5","author":"Ohmachi","year":"2021","journal-title":"Blood Adv"},{"key":"B74-20240828","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"key":"B75-20240828","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","article-title":"The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: A bio-CORAL study","volume":"29","author":"Thieblemont","year":"2011","journal-title":"J Clin Oncol"},{"key":"B76-20240828","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/10428190310001607151","article-title":"The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): Relationship to patient outcome","volume":"45","author":"Aref","year":"2004","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_2432_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:13:18Z","timestamp":1787757198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_2432_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":75,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_2432_21","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"2021-12-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}